ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Effect of Garlic Supplements on Opioids in Healthy Volunteers

This study is ongoing, but not recruiting participants.

Sponsors and Collaborators: Fred Hutchinson Cancer Research Center
National Cancer Institute (NCI)
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT00499460
  Purpose

RATIONALE: Garlic supplements may change the effectiveness of oxycodone used to relieve moderate or severe pain.

PURPOSE: This randomized phase I trial is studying how garlic supplements may change the effectiveness of opioids in healthy volunteers.


Condition Intervention Phase
Healthy, no Evidence of Disease
Drug: digoxin
Drug: garlic
Drug: midazolam hydrochloride
Drug: oxycodone hydrochloride
Procedure: gene expression analysis
Procedure: laboratory biomarker analysis
Procedure: liquid chromatography
Procedure: mass spectrometry
Procedure: pharmacological study
Procedure: protein expression analysis
Phase I

MedlinePlus related topics:   Dietary Supplements   

ChemIDplus related topics:   Oxycodone    Oxycodone hydrochloride    Midazolam    Midazolam hydrochloride    Midazolam maleate    Allium sativum extract    Digoxin   

U.S. FDA Resources

Study Type:   Observational
Official Title:   Modulation of Opioid Effects by Garlic Supplements

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Oxycodone hydrochloride pharmacodynamic measures

Secondary Outcome Measures:
  • Oxycodone hydrochloride pharmacokinetic parameters

Estimated Enrollment:   18
Study Start Date:   November 2006
Estimated Primary Completion Date:   April 2008 (Final data collection date for primary outcome measure)

Detailed Description:

OBJECTIVES:

  • Determine whether a CYP3A- and P-glycoprotein-dependent interaction exists between garlic supplements and a commonly used oral opioid analgesic (oxycodone hydrochloride) in healthy volunteers.

OUTLINE: This is a single-blind, randomized, crossover study. Participants are randomized to 1 of 2 arms.

  • Arm I: Participants receive oral garlic twice daily on days 1-28 and oral oxycodone hydrochloride on days 2 and 28. Participants then receive oral placebo twice daily on days 58-87 and oral oxycodone hydrochloride on days 60 and 85.
  • Arm II: Participants receive oral placebo twice daily on days 1-28 and oral oxycodone hydrochloride on days 2 and 28. Participants then receive oral garlic twice daily on days 58-87 and oral oxycodone hydrochloride on days 60-85.

In both arms, participants receive oral midazolam hydrochloride and oral digoxin once on days 29 and 86. Blood samples are collected periodically and examined by liquid chromatography-mass spectrometry (LC-MS) for CYP3A4 and P-glycoprotein phenotyping.

Blood and urine samples are collected after receiving oxycodone hydrochloride for pharmacokinetic-pharmacodynamic studies via LC-MS.

Pain response is assessed at baseline and periodically after oxycodone hydrochloride treatment via electrical stimulation and the cold pressor test. Side effects of oxycodone hydrochloride treatment are assessed via questionnaires and tests for cognitive function, manipulative dexterity, motor speed, and visual attention.

  Eligibility
Ages Eligible for Study:   21 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Criteria

DISEASE CHARACTERISTICS:

  • Healthy volunteer
  • Body mass index 20-32

PATIENT CHARACTERISTICS:

  • Not pregnant
  • No history of cardiopulmonary, liver, renal, endocrine, neurologic, or psychiatric disease
  • No anemia
  • No known adverse reactions to opioids, benzodiazepines, cardiac glycosides, or garlic supplements
  • No known allergy or hypersensitivity to sulfur-containing food or drugs
  • No significant gastrointestinal intolerance to lactose in dairy products
  • No recent history of alcohol or substance abuse
  • No history of or concurrent heavy daily consumption of allium vegetables (i.e., garlic, shallots, leeks, and chives)
  • No handicaps due to visual and hearing impairments
  • No resting heart rate < 50 beats per minutes
  • No abnormal cardiac rhythm by EKG
  • No unusually sensitive response or resistance to pain stimulation (cutaneous electrical stimulation and cold pressor test)
  • Must be right handed
  • No color blindness
  • No history of learning disabilities or dyslexia
  • Must be literate and proficient in English
  • Must be a nonsmoker

PRIOR CONCURRENT THERAPY:

  • No concurrent medication except oral contraceptives
  • No concurrent grapefruit or grapefruit juice
  • No other concurrent over-the-counter herbal products or herbal tea
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00499460

Locations
United States, Washington
Fred Hutchinson Cancer Research Center    
      Seattle, Washington, United States, 98109-1024

Sponsors and Collaborators
Fred Hutchinson Cancer Research Center
National Cancer Institute (NCI)

Investigators
Principal Investigator:     Danny Shen, PhD     Fred Hutchinson Cancer Research Center    
  More Information


Clinical trial summary from the National Cancer Institute's PDQ® database  This link exits the ClinicalTrials.gov site
 

Study ID Numbers:   CDR0000551927, FHCRC-2040.00, FHCRC-2040.00p
First Received:   July 10, 2007
Last Updated:   September 11, 2008
ClinicalTrials.gov Identifier:   NCT00499460
Health Authority:   United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
healthy, no evidence of disease  

Study placed in the following topic categories:
Oxycodone
Digoxin
Healthy
Midazolam

Additional relevant MeSH terms:
Anesthetics, Intravenous
Neurotransmitter Agents
Tranquilizing Agents
Molecular Mechanisms of Pharmacological Action
GABA Modulators
Physiological Effects of Drugs
Psychotropic Drugs
Central Nervous System Depressants
Anesthetics
Narcotics
Pharmacologic Actions
Adjuvants, Anesthesia
Sensory System Agents
Anesthetics, General
Therapeutic Uses
Hypnotics and Sedatives
GABA Agents
Anti-Anxiety Agents
Peripheral Nervous System Agents
Analgesics
Central Nervous System Agents
Analgesics, Opioid

ClinicalTrials.gov processed this record on October 06, 2008




Links to all studies - primarily for crawlers